

Epigenetics

Current Research and Emerging Trends

Edited by

Brian P. Chadwick

Department of Biological Science
Florida State University
Tallahassee, FL
USA



Copyright © 2015

Caister Academic Press
Norfolk, UK

www.caister.com

British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library

ISBN: 978-1-910190-07-4 (hardback)

ISBN: 978-1-910190-08-1 (ebook)

Description or mention of instrumentation, software, or other products in this book does not imply endorsement by the author or publisher. The author and publisher do not assume responsibility for the validity of any products or procedures mentioned or described in this book or for the consequences of their use.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher. No claim to original U.S. Government works.

Cover design adapted from images provided by Brian P. Chadwick and Zhuo Sun. The images show the distribution of the SMCHD1 protein (green) in female human nuclei (blue) by indirect immunofluorescence. The large staining foci in each nucleus corresponds to the territory of the inactive X chromosome.

Contents

	Contributors	v
	Preface	ix
1	The Multifaceted Roles of YY1 in the Establishment of the Cellular Epigenetic Landscape Raed Rizkallah	1
2	SETting up the Epigenome Through the Histone Methyltransferase SETDB1 Zhuo Sun and Brian P. Chadwick	23
3	Sirtuin Deacetylases in Fungi: Connecting Metabolism to Lifecycle Progression, Stress Response and Genome Stability Laura N. Rusche, Ashleigh S. Hanner, Justin M.H. Heltzel, Kristen M. Humphrey, Shivali Kapoor and Christopher B. Rupert	53
4	Development-linked Differences in Cytosine 5-Hydroxymethylation in Mammalian DNA: Relationship to 5-Methylcytosine and Function Melanie Ehrlich, Michelle Lacey, Guoqiang Zhang, Kenneth C. Ehrlich and Sriharsa Pradhan	77
5	The Identification of Mammalian Proteins Involved in Epigenetics Luke Isbel, Harry Oey and Emma Whitelaw	105
6	Chromatin-mediated Response to Stimuli Daniel L. Vera, Lauren A. Cole, Benjamin Hoffman and Jonathan H. Dennis	125
7	The Epigenetics of Centromere Function Justyne E. Ross, Shannon M. McNulty and Beth A. Sullivan	133
8	Dosage Compensation in Frogs and Toads John H. Malone	167
9	Ingenious Genes: The Diverse Roles of Long Non-coding RNA in Regulatory Processes Emily M. Darrow and Brian P. Chadwick	185
10	Epigenetic Mechanisms in Rett Syndrome Janine M. LaSalle	199

11	The Long and Short of Facioscapulohumeral Muscular Dystrophy Sunny Das and Brian P. Chadwick	217
12	The Epigenetics of Nuclear Reprogramming to Pluripotency Theodore P. Rasmussen	255
13	Emerging Role of the Guanine-quadruplex DNA Secondary Structure in Epigenetics Aradhita Baral, Dhurjhoti Saha and Shantanu Chowdhury	271
14	Clinical Epigenetics in Cancer María G. García, Estela G. Toraño, Agustín F. Fernández and Mario F. Fraga	285
15	Environment and the Epigenetic Transgenerational Inheritance of Disease Ingrid Sadler-Riggleman and Michael K. Skinner	297
16	Metabolic Inputs into Epigenetics Scott J. Bultman	307
17	Environmental Exposures: Impact on the Epigenome Jaclyn M. Goodrich and Dana C. Dolinoy	327
	Index	349
	Colour Plate	A1

Preface

What an exciting time in biology we find ourselves in. Many complex genomes are deciphered (Lander *et al.*, 2001; Mouse Genome Sequencing Consortium *et al.*, 2002), leaps and bounds are being made in stem cell biology (Takahashi *et al.*, 2007; Takahashi and Yamanaka, 2006; Thomson *et al.*, 1998), and molecular tools are being refined for precise editing and engineering of DNA (Carroll, 2011; Jung and Sander, 2013; Mali *et al.*, 2013). On top of all this, our understanding and appreciation for epigenetics has made phenomenal advances since the term ‘epigenetics’ was first put forward by Waddington in the 1940s to unite the fields of genetics and developmental biology (Waddington, 1942). Initially relating to developmental programming, today the designation of epigenetics is more focused and can be defined as the study of the mitotic and/or meiotic

heritability of gene expression triggered through a transient initiating event that occurs in the absence of change to the DNA sequence (Berger *et al.*, 2009; Felsenfeld, 2014; Russo *et al.*, 1996).

Despite the many advances, there is so much more yet to be learned about this complex, yet fascinating topic. For example, as illustrated in Fig. 1, who directs and initiates whom? DNA methylation or histone modifications? What about the role of RNA, or DNA structural forms? In my opinion, we are but at the base of the mountain and have an exciting and long adventure of discovery as we clamber ahead.

This book begins with several chapters that focus on epigenetic processes. We start with a discussion of the multifunctional zinc finger protein YY1 (Chapter 1) that performs numerous central roles in epigenetic phenomena.




Figure 1 What is the epigenetic hierarchy? Which comes first, DNA methylation or histone modifications? Or is it RNA or the act of transcription, and what role does the DNA have in setting up the epigenome?

Next we transition to two chapters that relate to histone-modifying enzymes. The first focuses on the versatile role of the histone methyltransferase protein SETDB1 in establishing and maintaining gene silencing (Chapter 2), whereas the second discusses the multifaceted role of sirtuins in fungal biology (Chapter 3). The next chapter discusses the distribution and detection of the DNA modification, 5-hydroxymethylcytosine in the genome, and how this relates to development (Chapter 4). After this chapter, various approaches to identify proteins involved in epigenetic processes are discussed, including the remarkable power of an *N*-ethyl-*N*-nitrosourea mutagenesis screen to generate mouse lines with mutations in epigenetic factors that enhance or suppress variegated transgene expression (Chapter 5). This is followed by a chapter that focuses on the global response of chromatin in response to stimuli (Chapter 6), before a discussion of the complex nature of chromatin and epigenetics in defining the centromere of eukaryotic chromosomes (Chapter 7). The next chapter is a broad discussion of dosage compensation with a particular focus on what is known in frogs and toads and why these animals make ideal models to further investigate this process (Chapter 8). The first part of the book is rounded off with a discussion of long non-coding RNAs in epigenetic processes (Chapter 9).

The next section of the book highlights two human genetic disorders that are directly impacted by epigenetics. The first provides an in depth and current review of the autism spectrum disorder Rett syndrome, which is caused by mutations in the methyl-DNA binding protein MECP2, whose gene is located on the X-chromosome and the disease is therefore also impacted by the mammalian dosage compensation pathway, X-chromosome inactivation (Chapter 10). The second disease focused chapter provides an in depth look at the progressive muscle degenerative disorder facioscapulohumeral muscular dystrophy, a complex disease that is impacted by many epigenetic influences (Chapter 11).

Finally, the last section of the book focuses on relatively new aspects of epigenetics. We start with a discussion of challenges and approaches to reprogramming the epigenome (Chapter 12), followed by a discussion of the potential for G4 quadruplex structures as a means for epigenetic inheritance (Chapter 13). The book is then rounded off with four chapters that address current topics in epigenetics. The first discusses the application of epigenetics in cancer diagnosis, prognosis and therapy (Chapter 14). The second (Chapter 15) focuses on transgenerational inheritance: inheritance of phenotype in the absence of exposure (Fig. 2). The third discusses the influence of metabolites on the epigenome (Chapter 16), and the final chapter (Chapter 17) discusses the impact of the environment on our epigenome, an area of growing concern (Fig. 3).

I would like to thank all the contributors for their time and effort in making this book happen, and hope that you, the readers, will enjoy and be as enlightened as I was in its preparation.

Dr Brian P. Chadwick



Transgenerational inheritance: A parents redemption

Figure 2 Can we now blame (at least in part) our great grandmother or our grandfather for epimutations that impact us? What are we doing, unbeknownst to us, that will impact our lineage several generations removed?




Figure 3 We now know how some environmental toxicants impact our epigenome and increase susceptibility to disease. However, what about those natural or man-made agents that are not currently on our radar?

References

- Berger, S.L., Kouzarides, T., Shiekhhattar, R., and Shilatifard, A. (2009). An operational definition of epigenetics. *Genes Dev.* 23, 781–783.
- Carroll, D. (2011). Genome engineering with zinc-finger nucleases. *Genetics* 188, 773–782.
- Felsenfeld, G. (2014). A brief history of epigenetics. *Cold Spring Harb. Perspect. Biol.* 6, 1–10.
- Joung, J.K., and Sander, J.D. (2013). TALENs: a widely applicable technology for targeted genome editing. *Nat. Rev. Mol. Cell. Biol.* 14, 49–55.
- Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., et al. (2001). Initial sequencing and analysis of the human genome. *Nature* 409, 860–921.
- Mali, P., Esvelt, K.M., and Church, G.M. (2013). Cas9 as a versatile tool for engineering biology. *Nat. Methods* 10, 957–963.
- Mouse Genome Sequencing Consortium, Waterston, R.H., Lindblad-Toh, K., Birney, E., Rogers, J., Abril, J.F., Agarwal, P., Agarwala, R., Ainscough, R., Alexandersson, M., et al. (2002). Initial sequencing and comparative analysis of the mouse genome. *Nature* 420, 520–562.
- Russo, V.E.A., Martienssen, R.A., and Riggs, A.D. (1996). Epigenetic mechanisms of gene regulation (Cold Spring Harbor Laboratory Press, Plainview, NY, USA).
- Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131, 861–872.
- Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126, 663–676.
- Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S., and Jones, J.M. (1998). Embryonic stem cell lines derived from human blastocysts. *Science* 282, 1145–1147.
- Waddington, C.H. (1942). The epigenotype. *Endeavour* 1, 18–20.

A

Acetyl-CoA 308, 314–318, 324
 Adenomatous Polyposis Coli *see* APC
Agouti viable yellow (Avy) 107, 297, 305, 308–310, 323, 331, 334, 343
 Alpha satellite 134, 140–141, 143–147, 149–150, 156, 158, 160–161, 163, 165, 268
see also Centromere
 Angelman syndrome 8, 17, 200, 215, 216
 APC 15
 Apoptosis 1, 13, 17–18, 20, 192, 197, 231, 244, 244, 247, 287, 293, 299
Arabidopsis thaliana 28, 46, 50, 135, 141, 154, 159, 165, 197, 240, 305
 Autism x, 39, 42, 168, 179, 182, 200, 214–216, 312

B

Barr body 41, 175–176
 Beckwith–Wiedemann syndrome 8
 Bisphenol A 298, 301, 304–305, 312, 321, 333, 342–347
 BMI1 6
 BRCA1 117, 119, 288–289, 292, 295, 332
 Chromodomain 28, 31, 44, 47, 49, 107, 111, 114, 120, 122

C

Caenorhabditis elegans 26, 35, 40, 44, 50, 131–132, 135, 158, 179, 276, 298, 304, 317–318, 321
 CAF1 28–30, 46
 Cancer x, 1, 7–8, 13–20, 23, 37–39, 42, 45–46, 48, 52, 89, 98–101, 114, 118, 128–129, 133, 177, 179, 192, 194, 196, 210–12, 231, 233, 247, 249–250, 252, 268, 272, 275, 279–281, 285–296, 301, 307–308, 312, 316, 319–325, 328, 330–333, 335, 339, 342–347
 CCCTC-binding factor *see* CTCF
 Cell cycle 6, 15, 16, 18–21, 47, 64, 68, 71, 73–74, 100–101, 113, 115, 121, 123, 127, 131, 134, 136, 138, 141, 151, 153, 155, 157–160, 164, 239–240, 268, 287–288, 316, 323
 Centromere 26, 40, 49, 60, 68–69, 114, 118, 120, 133–166, 223, 235, 260
see also Alpha satellite
 Centromere proteins
 CENP-A 133–141, 143–146, 148–166
 CENP-B 134, 143, 145, 150, 156, 165

CENP-C 113, 115, 119–120, 134, 141, 143, 148, 150, 152–153, 155–156, 158, 160, 164
 ChIP 3, 8–9, 11, 78, 82–83, 86, 93, 95, 114, 116, 149–150, 186, 206–207, 236, 238, 286, 310, 321
 Chromatin assembly factor 1 *see* CAF1
 Chromatin immunoprecipitation *see* ChIP
 Chromatin remodelling 4–5, 28–29, 51, 105–106, 108–109, 111, 113–114, 116, 120, 125–128, 130, 139–141, 241, 261, 265–265, 276, 278, 307–308, 318–319, 332
 Chromodomain (CD) 25, 27, 31, 42, 44, 47, 51, 119, 138
see also HPI
 Chromodomain helicase DNA binding protein 31, 138
 Chromoshadow domain 25
 Circulating free DNA (CFDNA) 287
 Clr4 25, 69–70, 107, 119–120
 Competing endogenous RNAs 189
 Copy number variation (CNV) 39, 168, 181, 183, 200, 224, 233
 CpG 3, 9, 11, 17, 27–29, 31, 34, 41, 43, 47, 49, 50, 80–86, 88, 90, 92–99, 101–103, 115–118, 199–202, 205–207, 209–214, 216, 220, 229–230, 233–237, 240–241, 243, 245–246, 255–256, 258–261, 265–268, 274–275, 279–282, 285, 287, 291–295, 307, 311–313, 315, 322, 330, 338–340, 346
see also DNA modifications
 CpG Island (CGI) 83–86, 91–94, 96–97, 233, 240–241, 285, 287
see also CpG
 Cryptic loci regulator 4 *see* Clr4
 CtBP 4, 6, 21, 123
 CTCF 4, 8, 10–11, 16–19, 34, 49–50, 84, 93, 95, 101–102, 196, 229, 233–235, 239, 246–247, 249, 251

D

D4Z4 112, 218–220, 222–230, 232–252, 254
see also Macrosatellite
 Deacetylation 5–6, 21, 25, 48, 53–54, 58–60, 63–64, 69, 71–74, 161, 265, 317–319, 322, 345
see also HDAC
 Defective in methylation-5 (DIM-5) 27–28, 52, 136
 DICER 154–155, 160–161, 193, 197
see also RNA interference
 Diethylstilbestrol (DES) 298, 303, 304, 343, 345

- Differentially methylated regions (DMR) 7, 300, 345
see also Genomic imprinting
- Dioxin 299, 301, 304, 331–333, 335, 342–343, 345, 347
- DNA methyltransferases
 DNMT1 31, 35, 37, 80–81, 109–110, 115, 119–120, 123, 205, 234, 256, 260–261, 307–308, 331, 334, 339
 DNMT3A 31, 35, 37, 45, 80, 96, 97, 100, 122, 205, 216, 251, 256, 286, 293, 304, 307, 334, 339
 DNMT3B 31, 35, 37, 80, 96–97, 109–110, 114–115, 120, 122–124, 137, 160, 234–235, 241, 249, 251, 286, 307
 DNMT3L 31, 41, 43–44, 47, 80, 101
- DNA modifications
 5-carboxylcytosine (5caC) 43, 78–79, 102, 313
 5-formylcytosine (5fC) 78–79, 102, 313
 5-hydroxymethyl-cytosine (5hmC) 35, 77–98, 100–101, 205, 207, 214, 313
see also Hydroxymethylation
 5-hydroxymethylcytosine x, 35, 43–45, 50–51, 77–79, 81, 85, 89, 93, 95, 97–103, 216, 270, 324
 5hmC 35, 77–98, 100–101, 205, 207, 214, 313
 5mC 35, 37, 77–81, 83–98, 100, 313
- DNA repair 1, 12, 14, 26, 29, 41, 48, 64, 65, 69, 73–74, 88–89, 119, 125, 140, 247, 288–289, 292, 323
- DNase 108, 126–127, 130, 206–207
- Dosage compensation x, 10, 169–183, 190, 202
see also X-chromosome inactivation
- DOT1L 109, 111, 121, 123, 265, 314
- Drosophila melanogaster* 5–6, 16–19, 21, 23, 25–27, 30, 35–36, 40–51, 105, 107–108, 111–112, 117–124, 132, 135, 138–139, 147, 149, 151–154, 156, 158–165, 168–171, 175, 177–183, 236, 317, 321
- DUX4 112, 218–220, 225–250, 252–254
see also D4Z4
- DXZ4 4, 12, 19, 233–234, 247, 249
see also Macrosatellite
- E**
- EED 6, 10, 19–21, 49
- Embryonic stem cells 11, 27, 31, 40, 45–49, 51–52, 77, 80, 82, 99–103, 118, 120–121, 161, 188, 193–196, 204–205, 213, 216, 228, 261, 267–269, 275, 289, 300–301, 315
- Endocrine-disrupting chemicals (EDCs) 327, 333, 335, 337–338
- Endogenous retroviruses (ERV) 23, 35–36, 37–41, 45–50, 231
- Enhancer 1, 11, 13, 16–19, 23, 25, 36–38, 41–43, 49, 51–52, 77, 82–87, 91–95, 98099, 101–102, 108, 111, 123, 189–191, 194, 196, 229, 239, 241, 249, 252, 256, 320
- Enhancer-blocking 16–17, 249, 252
- Enhancer of variegation (E(var)) 105–106, 108–112
- Enhancer of Zeste 16, 18, 25, 42, 45, 107, 121, 190, 238
see also EZH2
- Enhancer RNAs (eRNA) 190–191
- Epimutation x, 297, 300–305
- ERG-associated protein with a SET domain (ESET) 27, 41–43, 45–46, 49–52, 121
- Escherichia coli* 75, 77, 196, 271, 273, 277, 281, 324
- ESCs 27, 33, 35, 37–38, 44, 99, 119, 188, 205–207, 228, 241, 257, 259–266
- ETS-related gene (ERG) 28, 51
- Euchromatin 12, 24, 26, 36, 50, 114, 136, 140, 146, 152, 156, 160, 165, 190, 233, 236, 265
- EZH2/Ezh2 4–6, 10, 15–16, 19–21, 49, 84, 190, 195, 237–238, 314, 320, 334, 343
see also Enhancer of Zeste
- F**
- Facioscapulohumeral muscular dystrophy (FSHD) x, 112, 217–254, 281
see also D4Z4 and DUX4
- Folate 200, 214, 299, 308, 310–312, 321–324, 338, 343, 344
- G**
- G4 quadruplex x, 2, 13, 17, 271–283
see also G-quartet
- G9a 26–27, 31, 33, 36–37, 43, 49–50, 110, 112, 119, 123, 314
- Genomic imprinting 1, 7–10, 12, 14, 16–19, 21, 34, 40, 45, 48, 95, 121, 153, 185, 195, 212, 258–259, 268, 285, 292, 303, 321, 345
- GLP 26–27, 31, 33, 37, 43, 50, 110, 112, 123
- Gnas* 8–9, 18
- G-quartet 272, 277, 279–281, 283
see also G4 quadruplex
- Green fluorescent protein (GFP) 33, 108, 113, 146–147, 203, 264
- H**
- H19 8, 17–18, 50, 87, 185, 193, 249, 260, 269, 292, 321, 332, 335, 345, 347
- HDAC 4–7, 10, 13, 20, 25, 28, 31, 39, 75, 109, 111, 113, 206, 208, 236, 256, 259, 261, 263, 286, 290–291, 304, 316–318, 320, 338–339
see also Deacetylation
- HeLa cells 16, 113, 145–146, 345
- Heterochromatin 12, 15, 18, 24–31, 33–34, 36, 39–42, 44–51, 54, 57, 60, 64–72, 74, 105–108, 111–112, 114, 117–123, 136–137, 141, 145, 147, 150–152, 154–156, 158, 160–165, 170, 208, 233–238, 241, 251, 253–254, 256, 261, 265–266, 268–269, 282, 319
- Histone acetylation 24–25, 35, 44, 51, 58, 71–75, 117, 123, 138, 146, 150, 158, 183, 206, 215–216, 261, 266, 285, 288–290, 292, 295, 305, 314–317, 320–321, 323–325, 330, 339
see also Histone acetyltransferase
- Histone acetyltransferase (HAT) 4–5, 13, 24, 39, 45, 65, 72, 109, 115, 119, 124, 145–146, 256, 259, 308, 315–316, 320
see also Histone acetylation
- Histone code hypothesis 24
- Histone deacetylase *see* HDAC
- Histone deacetylase inhibitor 39, 50, 71, 141, 260–261, 268–269, 290–291, 293, 320, 324, 342–343
see also Trichostatin A and Valproic acid
- Histone demethylase 25, 42, 46–47, 51, 115, 117–119, 145, 190, 256, 258, 269, 308, 315, 321–322, 324, 338, 342

- Histone methylation inhibitor 15
- Histone methyltransferase x, 10, 16, 18–21, 23, 25, 40, 43–52, 69, 112, 119, 121, 123, 150, 190, 236–237, 252, 256
see also HMTase
- Histone modifications
- H3K27 5–7, 9, 11, 25, 48, 85, 207, 258, 260, 264, 269, 330
H3K27Ac 37–38, 42, 83, 85, 87, 93, 320
H3K27me 314
H3K27me2 140–141, 148
H3K27me3 27, 34, 37, 84, 93–94, 116, 136–137, 190, 192, 206, 236–238, 256, 265
- H3K36 35, 109, 206
H3K36me2 136, 140–141, 148
H3K36me3 93, 136–137, 140, 148, 152, 186, 190, 193, 256
- H3K4 11, 31, 51, 207
H3K4me 314, 319
H3K4me1 25, 27, 37–38, 83, 85, 93, 136, 191, 315
H3K4me2 40, 87, 115, 136–137, 140–141, 143–145, 148, 152, 154–155, 157–158, 190, 236, 246, 265
H3K4me3 25, 27, 34, 37, 45, 83–84, 93, 110, 116, 186–187, 190–191, 236, 256, 265, 315, 332
- H3K79 71, 109, 111, 123, 265, 314
- H3K9 5–6, 11, 25, 28, 31, 45, 49–51, 60, 68, 109–110, 112, 122, 136, 158, 163, 265, 269, 289, 334
H3K9Ac 39, 141, 144, 146, 261, 316–318
H3K9me 36, 150, 314,
H3K9me1 29, 42, 46, 315
H3K9me2 12, 29, 35, 136, 140–141, 143–144, 148, 154–155
H3K9me3 12, 27, 29–31, 33–39, 44, 46, 93, 110–113, 116, 137, 143–146, 152, 155–157, 176, 206, 23638, 241, 246, 256, 266–267
- H3S10 64, 141
- H4K16 60, 62–64, 317–318, 332
H4K16Ac 317–318, 332
- H4K20me1 42, 136–137
- H4K20me3 30, 37, 176
- Histone variants
- H2A Barr body deficient (H2A-Bbd) 23
- H2A.Z 94, 99, 116, 119–120, 130–131, 137, 152, 160, 163
- H2AX/H2A.X 12, 18, 116, 120
- H3.1 50, 138
see also CENP-A *under* Centromere proteins
- HMTase 23, 25–31, 33, 35–37, 190, 236
see also Histone methyltransferase
- Homolog of SIR Two proteins (Hst)
Hst1 59–63, 65–75
Hst2 55–57, 61–64, 66–67, 69, 71, 73, 75
Hst3 57, 60–62, 64, 66–75
Hst4 57, 60–61, 64, 66–67, 69, 71–73
- HOTAIR 52, 190, 197
- HOTTIP 190
- Hox genes 5, 19–21, 87, 89–91, 94–95, 99, 102, 190, 196, 298–300, 304, 343
- HP1 12, 15, 18, 25–34, 36–37, 40–51, 105–109, 112, 114, 117–119, 121–122, 150, 154, 163, 208, 236–238, 241, 246, 250, 254, 265
see also Chromodomain
- HT1080 cells 142, 145–146
- Human artificial chromosome (HAC) 142–147, 157–158, 161–163
- Huntington's disease 39, 42, 49, 87, 89, 102, 222, 251
- Hydroxymethylation 77–78, 80–81, 84–85, 88–90, 93, 95, 96–98, 100–101, 258, 343
see also ShmC *under* DNA modifications
- I**
- ICM 11, 12, 33, 80, 257, 260–265
see also Inner cell mass
- ICR 7–8, 18, 34–35, 48
see also Genomic imprinting
- Immunodeficiency, centromere instability and facial anomalies syndrome 1 (ICF1) 235–236, 249–251, 254, 286, 292
- Imprinting control region *see* ICR
- Inactive X chromosome 4, 11–12, 19, 24, 41, 44, 49, 71, 111, 120, 175, 182, 185, 190, 193–194, 233, 248–249, 251, 265
see also X-chromosome inactivation
- INCENP 114, 118, 156
- Induced pluripotent stem cells (iPSCs) 42, 205, 209–210, 216, 262, 264–267
- Inner cell mass 11–12, 33, 80, 100, 261
see also ICM
- INO80 4–5, 14, 16, 21, 318
- K**
- KLF4 188, 264–265
- KRAB 23, 28, 31–35, 39–40, 43–50, 122
- KRAB-associated protein-1 (KAP-1) 28, 41, 43, 48–49, 122
- L**
- LncRNA 153, 179, 185–197
see also Long non-coding RNAs
- Long intergenic non-coding RNA (lincRNA) 52, 186–190, 192, 194, 196–197, 292
- Long non-coding RNAs x, 10, 38, 153, 155, 157, 185–186, 188, 190, 193–197, 202, 231, 238, 246, 297, 301, 330, 337–338, 341
see also LncRNA
- Loss of imprinting 7, 14, 18, 212, 292
see also Genomic imprinting
- LTR 1, 36–38, 127, 156, 231, 243
- Lysine-specific demethylase 1 (LSD1) 25, 37, 42, 46–47, 49, 51, 114, 144–145, 190, 315
- M**
- macroH2A 23, 48, 54, 71, 73, 258, 261, 265, 268–269
- Macrosatellite 4, 12, 19, 112, 217, 220, 223–235, 245, 248–251
see also DXZ4 and D4Z4
- MCAF1 28–30, 36, 45, 51, 109
- MECP2 x, 27, 29, 42–43, 96, 100–101, 199–216, 338–339
- MeDIP/hMeDIP 78, 82–83, 86–86, 89, 93, 286

- Mesenchymal stem cells (MSCs) 34, 45, 48
 Metabolites *x*, 69, 74–75, 307–308, 313–314, 316, 318, 319–320, 325, 335, 344–346
 Methyl-CpG-binding domain (MBD) 27, 36, 39, 42, 199–202, 205, 207–208, 210, 236
see also Methyl DNA binding proteins
 Methyl DNA binding proteins
 MBD1 27–30, 43–44, 46–47, 49, 51, 109
 MBD2 115, 304
 MBD3 103, 265
 MBD4 115
see also MECP2
 Micrococcal nuclease (MNase) 126, 130
 MicroRNA 14, 21, 39, 48, 122, 176, 185, 194, 197, 243, 249, 264, 266, 268–269, 294, 331, 333–334, 340, 343
 Modifiers of murine metastable epialleles (MommeDs) 108–114, 116–117
 Morpholino 242–245, 252
 Myc 4, 14, 20, 47, 50, 112, 192–193, 197, 264–265, 273, 277, 279–280, 282
- N**
 NAD⁺ 53–58, 60, 65–67, 69–73, 75, 308, 314, 316–319, 321, 323
 NADH 53, 57, 314, 316–317, 319
 NANOG 38, 80, 189, 263–264, 269
 Neocentromere 147–154, 158–159, 161–162, 164–165
see also Centromere
 N-Ethyl-N-nitrosourea *x*, 35, 108, 246
Neurospora crassa 27, 50, 63, 70, 74, 136, 164, 193
 Nicotinamide 53–55, 316, 319, 321–322
 Nucleolus 69, 73, 156, 165, 175, 177, 182, 317, 319
 Nucleosome 23, 28–29, 32, 46, 50, 57, 60, 62, 64–65, 73–75, 95–96, 105, 109, 111, 115–116, 118, 120–121, 125–132, 134–137, 139, 150, 158–161, 163–166, 235–237, 255–256, 265, 269, 274–276, 278–281, 283, 304, 313–314, 319, 321, 327
 Nucleosome remodelling and deacetylase complex (NuRD) 28, 31–32, 37, 42, 48–49, 103, 114, 122, 265, 268, 318
- O**
 O-Acetyl-ADP-ribose 53–55, 71, 73–74
 Octamer-binding protein 4 (Oct4) 33, 38, 52, 259–261, 264, 267
 Oncometabolites 313, 325
 Oxidative bisulphite sequencing (oxBS-seq) 79, 83, 97
- P**
 p53 2, 4, 14–15, 17, 21, 70, 101, 192, 194, 231, 243, 250, 253, 266, 290
 Painting-of-fourth (POF) 36, 44–45, 121, 180
Peg3 8–9, 18, 250
 Persistent organic pollutants (POPs) 327, 331–333, 335–338, 344
 PHO 5–7, 126–127, 131–132
 PHO5 126–127, 131–132
 Phosphorylation 13, 20, 24, 27, 47, 57, 64, 136–138, 158, 163, 166, 196, 208, 211–213, 215–216, 236, 256, 285, 308, 315–316, 319, 321
 Phthalates 299, 301, 333, 335, 341, 343–347
 Plant homeodomain (PHD) 28, 31, 41, 44–45, 49, 51, 107, 114, 122
 Pluripotency 23, 33, 38, 43, 49–50, 80, 99, 188–189, 192, 194–195, 255, 257, 260, 262–265, 268–269, 293, 315
 Polyadenylation 38, 201–202, 210–211, 225
 Polycomb group (PcG) 1, 4–7, 9–10, 12, 14–21, 41–42, 47–49, 84, 93, 101, 113, 115, 121–122, 185–189, 191–192, 197, 238, 247, 264
see also PRC1 and PRC2
 Polycomb response element (PRE) 5–7, 20
 Position effect variegation (PEV) 25, 30, 42, 46, 50, 105–107, 118–124, 147, 158, 165, 249
 Prader-Willi syndrome 8, 10, 17, 35, 42
 PRC1 5, 6, 264
see also Polycomb group
 PRC2 5–6, 10, 15, 84, 189–190, 193, 197, 238, 251
see also Polycomb group
 Proliferating cell nuclear antigen (PCNA) 29, 48, 109, 115, 119, 280
- R**
 Rb 14, 273, 316
 Replication timing 151–152, 162, 175, 239, 252, 322
 Resveratrol 317, 320, 346
 Rett syndrome (RTT) *x*, 89, 199, 201–216
 Rex1 9, 18
 Rif1 110, 112, 118–119, 123
 RING1 6
 Ring finger 16, 31, 110
 RITS 154–155, 165
 RIZ 26, 42
 RNA interference (RNAi) 8, 29, 31, 33, 35–36, 38, 71, 80, 105, 113–114, 118, 120, 124, 152, 154, 156, 159–161, 163, 165, 188, 192, 242–243, 245, 316, 318
 RNA polymerase 17, 21, 58, 60, 62, 64, 72, 95, 99, 102, 116, 118, 154, 159, 161, 164, 186, 196, 238, 278–280
- S**
Saccharomyces cerevisiae 54, 56–61, 63–75, 126–127, 131–132, 134–135, 139, 142–143, 151, 153–154, 160–163, 190, 195, 276–277, 279–282, 318
 S-Adenosylmethionine (SAM) 307–311, 314–315, 319, 324, 332, 338–339, 344
Schizosaccharomyces pombe 25, 60–61, 63–64, 68–69, 71–72, 107, 134–135, 138, 141–142, 149, 151–152, 154–156, 160
 Serum response factor 3, 18
 SETDB1 *x*, 23, 25–49, 51–52, 109–110, 121–122
 SETDB2 26–27
 Set-domain 23, 26–28, 42–44, 46, 50, 52, 107, 120–121, 314
 shRNA 11, 113–114, 117, 188, 237, 240, 243, 247, 264
see also RNA interference
 Silent Information Regulator proteins
 Sir1 65, 75
 Sir2 54–75, 321
 Sir3 54, 60, 65, 71–72
 Sir4 56–57, 66–67, 71–72
 Silver-Russel syndrome 8
 SIN3A 28, 42, 51, 84, 109, 113, 123, 202, 208

- SIN3B 28
 siRNA 113–114, 139, 154–156, 188, 192, 238, 240
see also RNA interference
 Sirtuin x, 53–75, 308, 316–319, 322–323
 Small ubiquitin-related modifiers (SUMO) 30–32, 44, 46, 48, 50–51
 SNRPN 10, 20
 Somatic cell nuclear transfer (SCNT) 257, 259–261, 267, 269
 SOX2 38, 188, 264
 Splicing 27, 32, 73, 77, 81, 83–84, 95, 98, 101–102, 170, 182, 186, 191, 196, 200–201, 205, 207, 213, 214, 216, 228, 231, 238, 241, 244
 SRY 32, 47, 48
 Structural maintenance of chromosomes hinge domain 1 (SMCHD1) 110–112, 116, 118, 120–121, 220, 229–230, 234–235, 237, 240–241, 244–248, 250–252, 254
 SUMO-interacting motifs (SIM) 31–32
 Sumoylation 4, 14, 16, 30–31, 44, 236
 Suppressor of variegation 25, 42, 50, 105, 107, 123
 Suv39 26–31, 33, 36–37, 43, 45–48, 107, 112, 119, 150, 158, 237–238, 241, 265, 314
 SWI/SNF 109, 111, 13–116, 119, 318
 Switching-deficient 6 (SWI6) 25, 60, 69, 107, 121, 154
- T**
 TBP 4
 Telomere 60, 65, 68–72, 74–75, 107, 110, 112, 117, 119–120, 123, 142–143, 152, 160, 164, 223–224, 229, 236, 239–241, 245–246, 248, 250, 252–254, 271–272, 277–278, 280–282
 Ten-eleven translocation (TET) 35, 101, 264, 313
 TET1 35, 45, 50–51, 77, 79–84, 90, 94–95, 99–103
 TET2 45, 51, 77, 80–81, 83–84, 87, 90, 94–95, 99–100, 264, 268, 322
 TET3 77, 80, 84, 94–95, 101, 258
 TIF1A 114
 TIF1B 28
 Toxicant xi, 297–303, 327–330, 333, 337–340
 Transcription intermediary factor 106, 118
 Transcription repression domain (TRD) 29, 200, 201, 208
 Transcription start site (TSS) 82–87, 92–94, 98
 Transgenerational inheritance x, 110, 119, 297–305, 309, 311–312, 321, 323, 329, 337, 341, 345
 Transposable element 36, 38, 41, 44–45, 47, 156, 170, 176, 179, 267, 310, 324
 Trichostatin A (TSA) 71, 141, 150, 261, 268, 290
see also Histone deacetylase inhibitor
 TRIM28 23, 28–35, 37–38, 40, 42, 49–50, 106, 109–113
 Tsix 10–11, 18–19, 202
 Tudor domain 27–29, 31, 41, 44, 46, 48, 51, 110
- U**
 Ubiquitin 30, 51, 64, 71, 110, 116, 192, 231
 Ubiquitination 24, 197, 236, 256, 264, 280, 285, 318, 322
- V**
 Valproic acid 260, 269, 295
see also Histone deacetylase inhibitor
 Vinclozolin 298–304
- W**
 Waddington ix, xi, 297, 305
 William's syndrome 111
- X**
 X-chromosome inactivation (XCI) x, 1, 10–12, 16–17, 19, 21, 43, 46–47, 111, 118, 153, 169, 176, 177, 179–181, 183, 189, 196, 199, 202–203, 210–211, 214–216, 240, 247, 251, 262, 265, 267, 285
 X-chromosome inactivation center (Xic) 10–11, 16, 18, 193
see also X-chromosome inactivation
Xenopus laevis 6, 20–21, 127, 132, 174, 176–183, 232, 259
 X-inactive specific transcript 185, 193
see also X-chromosome inactivation *and* Xist
 Xist 8, 10–11, 17–19, 170, 179, 185, 188–190, 193–194, 196, 205
see also X-chromosome inactivation *and* X-inactive specific transcript
- Y**
 YY1 ix, 1–21, 234, 238, 250, 265
- Z**
 Zfp57 34–35, 46, 48, 321
 Zinc finger ix, 2, 4–6, 13, 17, 23, 28, 32–33, 41, 44, 45–46, 49–50, 111–112, 115–117, 121–123, 244, 251, 274, 276–279, 281